| Literature DB >> 32587945 |
Julian M Gaitán1, Elizabeth A Boots1, Ryan J Dougherty1,2,3, Yue Ma1, Dorothy F Edwards1,4,5, Carol C Mitchell6, Bradley T Christian1,7, Dane B Cook2,3, Ozioma C Okonkwo1,4,5.
Abstract
A growing body of evidence supports that aerobic exercise can decrease the risk of future cognitive impairment and Alzheimer's disease (AD). There is a pressing need to rigorously determine whether cognitively normal yet at-risk individuals stand to benefit from the protective effects of exercise. The present study will test the feasibility of an aerobic exercise intervention in such a population and inform the design of a larger-scale randomized, controlled trial examining the effect of aerobic exercise on biomarkers of AD in late-middle-aged, at-risk individuals. This was a single-site, 1 : 1 block-randomized, parallel, two-arm trial. Cognitively normal participants aged 45-80 with documentation of familial and genetic AD risk factors were randomly assigned to one of two interventions. The Usual Physical Activity group was provided educational materials about exercise. The Enhanced Physical Activity intervention delivered 26 weeks of individualized and supervised aerobic exercise. Exercise duration and intensity were incrementally increased to 150 min/week and 70-80% of heart rate reserve, respectively. Retention and adherence were measured to assess study feasibility. In addition, pre- and post- intervention differences between the two arms were evaluated for cardiorespiratory fitness, physical activity, brain glucose metabolism, cerebral structure, vascular health, memory, executive function, and mood. Data from randomized controlled trials of exercise training are needed to identify the proper exercise prescription for reducing accumulation of AD biomarkers in cognitively normal individuals. The current trial will contribute to filling that gap while informing the design of large-scale trials.Entities:
Keywords: Cardiorespiratory fitness; exercise; magnetic resonance imaging; physical activity; positron emission tomography; preclinical Alzheimer’s disease
Year: 2020 PMID: 32587945 PMCID: PMC7306918 DOI: 10.3233/ADR-200180
Source DB: PubMed Journal: J Alzheimers Dis Rep ISSN: 2542-4823
Fig. 1Study schedule. Progression of study procedures from screening through post-intervention assessment. FDG-PET, 18F fluorodeoxyglucose positron emission tomography; MRI, magnetic resonance imaging; PA, physical activity.
Inclusion and exclusion criteria
| Inclusion Criteria | – 45–80 years old |
| – Documented positive/negative family history of AD | |
| – Physically inactive (<150 min/week moderate intensity assessed by TAPA [ | |
| – Physician consent to participate | |
| – Willing and able to complete aerobic exercise intervention and all assessments | |
| – English fluency for cognitive testing purposes | |
| Exclusion Criteria | – Pregnancy |
| – Diabetes | |
| – Diagnosis of significant neurological disease (including mild cognitive impairment or AD) or significant head trauma followed by persistent neurologic deficits | |
| – Known structural brain abnormalities | |
| – Contraindication to MRI (e.g., pacemaker, ferrous metal implant) | |
| – Contraindications to exercise testing (e.g., recent myocardial infarction) | |
| – Finding from exercise testing prohibiting safe participation in aerobic exercise intervention (e.g., 3rd degree AV block) | |
| – Psychiatric condition (e.g., major depression, bipolar disorder) per DSM-IV criteria | |
| – History of alcohol or substance abuse per DSM-IV criteria | |
| – Significant medical condition affecting cognition or other outcome measures | |
| – Severe untreated hypertension | |
| – Use of: antipsychotic medications (e.g., non-SSRI antidepressants, neuroleptics); cardiac glycoside medications; investigational agents | |
| – Cancer in the previous five years (except skin cancer) |
Fig. 2Flowchart of study design and recruitment. The final sample of participants whose data is to be analyzed was obtained after a thorough screening process; one participant had to discontinue the intervention after randomization.
Fig. 3Enhanced PA intervention progression. Participants in the Enhanced PA intervention completed a gradual buildup of exercise duration and intensity over the course of the first seven weeks; they maintained duration and relative intensity from weeks seven through 26. HRR, heart rate reserve.